FDA and EMA Accept Tebentafusp Applications for Metastatic Uveal Melanoma

Source: OncLive, August 2021

The FDA and the European Medicines Agency (EMA) have accepted applications seeking the approval of tebentafusp (IMCgp100) for use in the treatment of adult patients with HLA-A*02:01–positive metastatic uveal melanoma.1

In the United States, the regulatory agency has granted priority review to the biologics license application for the agent.

READ THE ORIGINAL FULL ARTICLE